BCIQ Profiles

Company Profile Report

Rinvoq approval bolsters AbbVie's autoimmune portfolio

With Humira adalimumab set to face increasing biosimilar competition internationally this year, AbbVie has notched its second U.S. regulatory win for a successor to its primary revenue driver with FDA’s approval Rinvoq upadacitinib on Friday for rheumatoid arthritis.

The oral

Read the full 396 word article

How to gain access

Continue reading with a
two-week free trial.